Treatment Options From 5 Experts for People With Multiple Myeloma
An Interactive Decision Support Tool: Treatment Options From 5 Experts for People With Multiple Myeloma

Released: October 24, 2023

References

Al Hamed R, Bazarbachi AH, Malard F, et al. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9:44.

Atrash S, Tullos A, Panozzo S, et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J. 2015;5:e272.

Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019; 394:2096-2107.

Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116:4745-4753.

Bringhen S, Milan A, D'Agostino M, et al. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib: a consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. J Intern Med. 2019;286:63-74.

Centers for Medicare & Medicaid Services. Medicare intermediary manual. cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R1805A3.pdf. Accessed July 28, 2023.

Ciltacabtagene autoleucel [prescribing information]. Horsham, PA: Janssen Biotech; 2022.

Daratumumab [prescribing information]. Horsham, PA: Janssen Biotech; 2019.

Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28:4976-4984.

Elotuzumab [prescribing information]. Princeton, NJ: Bristol Myers Squibb; 2018.

Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:1582-1596.

Gay F, Palumbo A. autologous transplantation in elderly multiple myeloma patients: is the procedure cost effective? Biol Blood Marrow Transplant. 2015;21:1705-1706.

Idecabtagene vicleucel [prescribing information]. Summit, NJ: Celgene; 2021.

International Myeloma Foundation. Withdrawal of Belnrep from the US market. myeloma.org/news-events/withdrawal-blenrep-us-market. Accessed July 28, 2023.

International Myeloma Working Group. IMWG guidelines for the management of treatment-emergent peripheral neuropathy in multiple myeloma. myeloma.org. Accessed July 28, 2023.

International Myeloma Working Group. IMWG guidelines for the prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. myeloma.org. Accessed July 28, 2023.

Isatuximab-irfc [prescribing information]. Bridgewater, NJ: Sanofi Aventis US; 2022.

Larocca A, Salvini M, De Paoli L, et al. Efficacy and feasibility of dose/schedule-adjusted Rd-R vs. continuous Rd in elderly and intermediate-fit newly diagnosed multiple myeloma (NDMM) patients: RV-MM-PI-0752 phase III randomized study. Presented at: 2018 2018 American Society of Hematology Annual Meeting; December 1-4, 2018. Abstract 305.

Laubach J, Garderet L, Mahindra A, et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2016;30:1005-1017.

Lenalidomide [prescribing information]. Summit, NJ: Celgene; 2019.

Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev. 2010;36(suppl 2):S24-S32.

Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431-440.

Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Eng J Med. 2022;387:495-505.

National Comprehensive Cancer Network. Clinical practice guidelines in oncology: multiple myeloma. v.3.2023. nccn.org. Accessed July 28, 2023.

O'Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018;182:222-230.

Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414-423.

Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma: an International Myeloma Working Group report. Blood. 2015;125:2068-2074.

Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomized, controlled, phase 3 study. Lancet Oncol. 2018;19:370-381.

Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-e548.

Rendo MJ, Joseph JJ, Phan LM, DeStefano CB. CAR T-cell therapy for patients with multiple myeloma: current evidence and challenges. Blood Lymphat Cancer. 2022;12:119-136.

Selinexor [prescribing information]. Newton, MA: Karyopharm; 2019.

Swaika A, Paulus A, Miller KC, et al. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol. 2012;10:155-159.

Teclistamab [prescribing information]. Horsham, PA: Janssen Biotech; 2022.

Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA. Myeloma bone disease: from biology findings to treatment approaches. Blood. 2019;133:1534-1539.

Terpos E, Zamagni E, Lentzsch S, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021;22:e119-e130.

van de Donk NWCJ, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016;127:681.

Vassilopoulos S, Vassilopoulos A, Kalligeros M, et al. Cumulative incidence and relative risk of infection in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based regimens: a systematic review and meta-analysis. Open Forum Infect Dis. 2022;9:ofac574.

Velasco R, Alberti P, Bruna J, et al. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(suppl 2):S52-S62.

Waxman AJ, Clasen S, Hwang WT, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4:e174519.

Access to and use of this Interactive Decision Support Tool titled, “An Interactive Decision Support Tool: Treatment Options From 5 Experts for People With Multiple Myeloma” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate people on potential treatment options for multiple myeloma. The information provided is based on guideline recommendations and expert guidance of Shaji K. Kumar, MD, Joseph Mikhael, MD, MEd, FRCPC, FACP, Suzanne Lentzsch, MD, PhD, Saad Z. Usmani, MD, MBA, FACP, Sagar Lonial, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the Clinical Care Options material, not those of Clinical Care Options, LLC; the accredited provider; or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “An Interactive Decision Support Tool: Treatment Options From 5 Experts for People With Multiple Myeloma” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2023 Clinical Care Options, LLC. All rights reserved.

Program Content